Business Wire

CA-MOUSER-ELECTRONICS

8.1.2020 16:42:11 CET | Business Wire | Press release

Share
Mouser Electronics and Grant Imahara Showcase Contract Manufacturing in “Engineering Big Ideas” Video Finale

Mouser Electronics , Inc. and celebrity engineer Grant Imahara today released the final Engineering Big Ideas video, the latest series in Mouser’s award-winning Empowering Innovation Together ™ program. To watch the enlightening video, go to https://mou.sr/EIT2019-4 .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200108005588/en/

The series’ final installment takes viewers to Silicon Valley, where Imahara meets with Beth Kendrick, President of Valley Services Electronics (VSE) — a full-service manufacturer that assembles custom printed circuit boards (PCB), specializing in low-volume and prototype electronics services. The Engineering Big Ideas series is supported by Mouser’s valued suppliers Analog Devices , Intel ® , Microchip Technology and Molex .

“Manufacturing is often one of the last and most important stops on the electronic design engineer’s journey to product creation,” said Glenn Smith, President and CEO of Mouser Electronics, an authorized global distributor of the newest semiconductors and electronic components. “In order to push products through to the finish line, it is essential for product engineers to be on the lookout for any red flags when selecting components for their products and then when choosing the right manufacturing partner.”

The new video goes behind the scenes with Kendrick and the VSE team, who share first-hand advice for new product innovators and highlight what creators should look for in a PCB assembly (PCBA) manufacturer to ensure a smooth go-to-market process. The team describes how they broke through the confines of offshore manufacturing norms and what that means for today’s innovators.

“Asking all of the key questions, the right how, why and what, to potential manufacturing partners is critical to ensuring your vision and product come to fruition. We are excited to showcase this last step,” Imahara added.

The global distributor’s Empowering Innovation Together program has been one of the most recognized and notable electronic component marketing programs since 2015, highlighting a range of innovative developments from IoT and smart cities of the future to robotics technologies .

To learn more about Engineering Big Ideas and all of Mouser’s Empowering Innovation Together series, visit www.mouser.com/empowering-innovation and follow Mouser on Facebook and Twitter .

About Mouser Electronics

Mouser Electronics, a Berkshire Hathaway company, is an award-winning, authorized semiconductor and electronic component distributor focused on rapid New Product Introductions from its manufacturing partners for electronic design engineers and buyers. The global distributor's website, Mouser.com, is available in multiple languages and currencies and features more than 5 million products from over 800 manufacturers. Mouser offers 27 support locations around the world to provide best-in-class customer service and ships globally to over 630,000 customers in 223 countries/territories from its 750,000 sq. ft. state-of-the-art facility south of Dallas, Texas. For more information, visit www.mouser.com .

About Grant Imahara

Well known in the engineering community, Grant Imahara has paired his engineering expertise with a successful TV and film career. In addition to his roles on MythBusters and BattleBots , Imahara has worked on many famous robotic characters, including R2-D2 from Star Wars , the talking robot skeleton sidekick Geoff Peterson from The Late Late Show with Craig Ferguson , and the Energizer Bunny.

Trademarks

Mouser and Mouser Electronics are registered trademarks of Mouser Electronics, Inc. Intel is a registered trademark of Intel Corporation in the United States and other countries. All other products, logos, and company names mentioned herein may be trademarks of their respective owners.

Link:

ClickThru

Social Media:

https://www.facebook.com/mouserelectronics/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye